MSD (Merck Sharp & Dohme AG) Switzerland appoints Ans Heirman, Ph.D. as the new Managing Director of MSD Switzerland, effective September 1st, 2020
Ein Dokument
mehr
Storys zum Thema Pharmakologie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical care
Munich (ots/PRNewswire) - - Newly presented data provide reassurance around edoxaban use in vulnerable populations of frail, elderly and renally impaired patients - Clinician's perception of frailty found to potentially be a better marker of clinical outcomes than age - The global ETNA-AF programme, which includes ...
mehrDEBIOPHARM'S NEW GENERATION RADIONUCLIDE THERAPY ADVANCES INTO CLINICAL RESEARCH IN THE FIGHT AGAINST LUNG CANCER
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
mehrETNA-AF-Europe Registry Data on LIXIANA®(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with Atrial Fibrillation
Munich (ots/PRNewswire) - - Publication highlights Europe-specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients[1] - Findings are ...
mehrNorgine B.V. Completes Important Regulatory Milestone For Angusta® (Misoprostol) In Europe For Oral Induction Of Labour
Amsterdam (ots/PRNewswire) - - Norgine will now seek to extend ANGUSTA®'s licence to a number of European countries - ANGUSTA®'s licence extension for these countries will be subject to national approvals Norgine B.V. (Norgine) today announced the successful completion of the Repeat Use Procedure (RUP) for ...
mehrDEBIOPHARM'S IAP ANTAGONIST SIGNIFICANTLY IMPROVES OVERALL SURVIVAL OF HIGH-RISK HEAD & NECK CANCER PATIENTS
Lausanne, Switzerland (ots) - Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of ...
mehr
UCB Half Year Report 2020
Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...
mehrNorgine; AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand
Waltham, Mass. and Amsterdam (ots/PRNewswire) - Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantag AMAG Pharmaceuticals, Inc. ...
mehrDavide Molho, DVM Joins Viroclinics Biosciences as Chief Executive Officer
Rotterdam, Netherlands (ots/PRNewswire) - Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company's CEO since 2011. This transition is part of a planned succession strategy. Dr. ...
mehrVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
mehrRates of Bleeding and Venous Thromboembolism (VTE) Events Reported After 12 Months of Edoxaban Treatment Considered Low by Real-world ETNA-VTE Study Investigators
Munich (ots/PRNewswire) - - Daiichi Sankyo presented five abstracts from the Global and European ETNA-VTE registry studies at ISTH 2020 Virtual Congress - Data are from 4,595 VTE patients (mean age 64) from 583 sites across Europe, Japan and other East and South-east Asian countries - Real-world study adds to the ...
mehrStephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck
Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...
mehr
NUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM
Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...
mehrMental Health Care Company COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
London (ots/PRNewswire) - - Piers Morgan appointed earlier in the year as Chief Financial Officer and Gary Gilmour as Director of Preclinical Research COMPASS Pathways, a mental health care company, announced today that it has made a number of new appointments to its leadership team. Trevor Mill joins the company as ...
mehrZhejiang Hisun Pharmaceutical Co. Ltd
Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir
Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly ...
mehrSwitching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...
mehrInternational Atherosclerosis Society
International Atherosclerosis Society Issues Call to Action to Improve Lipid Management Based on Survey Results to Address Patients' Residual Risk
Milan (ots/PRNewswire) - Article and slides can be found at https://www.athero.org/activities/survey or contact Karen Foy (karen.foy@athero.org) A new survey by the International Atherosclerosis Society (IAS) provided a 'snapshot' of the gaps in knowledge among clinicians that limit best practice. This web-based ...
mehrDebiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
Lausanne, Switzerland (ots) - Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program, to treat diseases related to dysbiosis of the human gut microbiome Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement ...
mehr
Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
LAUSANNE, SWITZERLAND & WAYNE, PENNSYLVANIA (ots) - Debiopharm, a Swiss-based, biopharmaceutical company, and Verity Pharmaceuticals Inc., a US based specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases, today announced having entered into an exclusive agreement that ...
mehrUCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
Brussels, Belgium (ots/PRNewswire) - - Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure - Staccato® Alprazolam could be a potential solution for ...
mehrZentiva Expands Production Capacity by Completing Acquisition of Ankleshwar Manufacturing Site
Prague (ots/PRNewswire) - Zentiva Group announces the completion of its acquisition of a manufacturing site in Ankleshwar, India, from Sanofi. The finalization of the deal increases the number of wholly-owned Zentiva production sites worldwide and will enable Zentiva to serve more people who are in daily need of our high quality, affordable medicines. "We are delighted ...
mehrAcquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention
Lausanne, Switzerland (ots) - - Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience - Kaiku's acquisition by the Swedish company Elekta allows thousands of cancer treatment centers to gain access to the ...
mehrTauRx Reveals Study Results That Offers New Hope for Treatment of Patients With Dementia
Aberdeen, Scotland and Singapore (ots/PRNewswire) - Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease In a paper published online in the Journal of Alzheimer's Disease ( https://doi.org/10.3233/JAD-191173 ) , TauRx reported that the drug it is developing for ...
mehrBreakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...
mehr
Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer
Loures, Portugal (ots/PRNewswire) - Hovione announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Operating Officer (COO), effective May 1st, 2020. Dr. Herbeaux held, over the past 20 years, multiple high-level leadership positions at Evonik, bringing to Hovione a proven commitment to develop a successful and globally active business. Based in Lisbon, ...
mehrData From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...
mehrMental Health Care Company COMPASS Pathways Concludes Successful Series B Investment Round
London (ots/PRNewswire) - $80m Raised Will Further the Development of Psilocybin Therapy COMPASS Pathways, a mental health care company, announced today that it has completed a successful $80m Series B investment round. This funding will expand upon COMPASS's lead programme in psilocybin therapy for treatment-resistant depression, supporting research into additional ...
mehrSOPHiA GENETICS Expands Its Executive Team, Naming Lara Hashimoto Chief Business Officer
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be responsible for Marketing, Product Management and Business Development. Lara Hashimoto joined the healthcare industry 20 years ago holding ...
mehrZentiva Extends Commercial Footprint By Completing Acquisition of CEE Business From Alvogen
Prague (ots/PRNewswire) - Zentiva Group a.s. confirms the closing of its previously declared acquisition of Alvogen's Central and Eastern European (CEE) business. The deal adds to Zentiva's continuing organic growth, reinforcing Zentiva's commercial footprint in Poland, Romania and Bulgaria, and expanding its ...
mehrUCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn targeting ...
mehr
Vorherige45678910111213Nächste